News & Insights

OIC portfolio company Oxehealth has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.

The two rounds have been underwritten by existing shareholders, which included a commitment from the Oxford Technology & Innovations EIS Fund (OTIF) advised by OIC.

OIC investee company SpyBiotech, which is developing a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor.

We’re excited to announce the launch of the first 2021 round of the Oxford Technology and Innovations EIS Fund (OTIF) advised by us and managed by Thompson Taraz!

• SpyBiotech Ltd is developing a novel “plug and play” vaccine platform technology targeting infectious diseases, cancer and chronic diseases.
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $32.5m round led by Braavos Investment Advisers.
• Lutz B. Giebel joins as Chair, strengthening governance as company expands clinical development and builds operational resource.

This holiday season is unlike any other, to finish off a year unlike any other we have known.

We’d like to take this opportunity to thank our companies, investors and co-investors for their patience and support in 2020.

Throughout this season and as we move into 2021, we wish you moments of peace amid the difficulties, and connections with your families and friends, even if they can’t be in person.

Best wishes

George, Ross, Christopher & James

– The OIC Partners